ITGA4 and B-cell chronic lymphocytic leukemia: Notably, such different behavior between CD49d+ and CD49d− CLL was documented in cohorts with different mean ALCs before treatment and involved patients enrolled in different clinical trials, named patient programs (NPP), and from the real world, thus implying that the observed effects did not occur because of the selection of a particular group of patients.